Device Trial Radar · NCT07853196
Effects of Hyaluronic Acid Complex and Dexamethasone on Pain, Swelling, and Trismus After Mandibular Third Molar Surgery
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Mar 5, 2026
Primary completion
Jul 25, 2026
Study completion Jul 25, 2026
Sponsor
- Lead sponsor
- Cyprus Health and Social Sciences UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 1, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aimed to comparatively evaluate the effects of a hyaluronic acid complex and dexamethasone on postoperative pain, swelling, and trismus following mandibular third molar surgery, compared with a control group. Participants were evaluated in three groups: a hyaluronic acid complex group, a dexamethasone group, and a control group. Postoperative pain, facial swelling, and limitation of mouth opening were assessed during the postoperative follow-up period to compare postoperative outcomes among the groups.
Conditions
- Postoperative Morbidity
Interventions
Hyaluronic Acid ComplexDrug
Monovisc® (Anika Therapeutics, Inc., Bedford, MA, USA), containing 22 mg/mL cross-linked, high-molecular-weight sodium hyaluronate, was used. A 0.2 mL volume of the preparation (equivalent to 4.4 mg sodium hyaluronate) was applied directly into the extraction socket using a sterile applicator. SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge was subsequently placed into the socket to enhance retention of the preparation.
DexamethasoneDrug
DEKORT® 8 mg/2 mL solution for I.M./I.V. injection (DEVA Holding A.Ş., Türkiye) was used. A 1.5 mL volume of the solution, corresponding to 6 mg dexamethasone, was absorbed into a SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge and placed directly into the extraction socket.
Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)Device
SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge (MS0005; 1 × 1 × 1 cm; Ethicon, Johnson \& Johnson) was placed directly into the extraction socket. In the control group, the gelatin sponge was used without hyaluronic acid or dexamethasone.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Postoperative Pain Assessed Using the Visual Analog Scale (VAS)Time frame: Postoperative days 1, 2, 3, and 7
- Facial Swelling Assessed Using Facial MeasurementsTime frame: Preoperatively and on postoperative days 1, 2, 3, and 7
- Trismus Assessed by Maximum Interincisal Mouth OpeningTime frame: Preoperatively and on postoperative days 1, 2, 3, and 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NEW Cyprus Health and Social Sciences University
Mórfou, Guzelyurt, Cyprus
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.